Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

The gene for Marie Unna hereditary hypotrichosis is located on chromosome 8p21.

This consensus report outlines Brazilian dermatologists' recommendations for treating alopecia areata, highlighting intralesional corticosteroids for localized cases and systemic therapy for extensive, active disease, along with monitoring side effects.

This study reports that yellow dots in a higher number per field of vision were the most consistent dermoscopic finding in severe cases of alopecia areata.

This study found that patients with alopecia areata had significantly lower serum levels of 25-hydroxy vitamin D compared to control subjects.

This study identified miR-200c-3p as influencing key genes in the EGFR resistance pathway, suggesting its potential theranostic role in addressing issues related to this pathway.

This article reviews alopecia areata treatments, noting varied outcomes, and reports no new clinical results.

This study outlines treatment options for alopecia, suggesting intralesional corticosteroids for localized adult cases and Janus Kinase inhibitors for severe cases, emphasizing a balance between hair regrowth rate and managing side effects.

This review discusses the role of cutaneous and intestinal microbiota in the development of alopecia areata, summarizing current literature without reporting new clinical results.

This review discusses the assessment and management of common causes of pediatric alopecia, highlighting the importance of dermatologist referral for unclear diagnoses, treatment failures, or scarring alopecia, and reports no new clinical findings.

The gene for Marie Unna hereditary hypotrichosis is located on chromosome 8p21, near the hairless gene.

This study found that people with alopecia areata have a higher likelihood of experiencing anxiety and depression, and a moderate negative impact on their quality of life compared to healthy individuals.

This review discusses the potential link between gut microbiota alterations and the onset and progression of alopecia areata, identifying it as a possible pathogenetic factor and therapeutic target, but reports no new clinical results.

This review discusses recent advances in understanding and treating alopecia areata, emphasizing the ongoing challenges and unmet needs in disease management; it reports no new clinical findings.

This review suggests that 308 nm excimer therapy may offer a well-tolerated non-pharmacologic option for alopecia areata, with more limited evidence for its effectiveness in lichen planopilaris and frontal fibrosing alopecia.

This review highlights that alopecia areata is influenced by genetic, autoimmune, and environmental factors, with emerging treatments like JAK-2 inhibitors showing promise for severe cases.

This study reports a unique case of identical twins experiencing alopecia areata at the same time, suggesting potential environmental triggers for this polygenic autoimmune condition.

This study found that the global prevalence of alopecia areata is estimated at 1.93%, affecting around 15.05 million people, with significant regional and demographic variations.

This study observed that the expression of hsa-miR-193a-5p was significantly higher in alopecia areata patients compared to healthy controls, suggesting its role in influencing disease progression through impact on specific signaling pathways and highlighting its potential as a therapeutic target.

In this study, researchers evaluated the stability and color changes of compounded minoxidil formulations used for alopecia, finding that while the formulations remained chemically and microbiologically stable for up to 380 days, significant color changes were observed, which likely do not affect the product's effectiveness.

This abstract presents a patient case study and does not report new research findings.

This study identified CD28, GZMB, and CD1C as key immune regulators in alopecia areata, highlighting CD28 as a potential therapeutic target with a promising safety profile, using a proteome-anchored multi-omics approach to uncover actionable targets for this autoimmune hair-loss disorder.

In this retrospective case series, baricitinib showed effectiveness in treating alopecia areata, with some potential benefits for psoriasis, but it may not be suitable for managing psoriatic arthritis in patients with these coexisting conditions.

In this retrospective case series, baricitinib showed effectiveness in treating severe alopecia areata but had mixed results for psoriasis and was not optimal for psoriatic arthritis in patients with coexisting conditions, suggesting further studies are needed.

This study described the incidence and prevalence of alopecia areata in Australia's primary healthcare population, finding the highest incidence in individuals aged 19 to 34, with males more affected than females.

This study observed that baricitinib treatment led to significant improvements in hair regrowth and quality of life scores in adults with severe alopecia areata over 24 weeks, with an acceptable safety profile as most adverse effects were transient.

In this study, researchers retrospectively analyzed five children with extensive and refractory alopecia areata treated with mesalazine, observing complete hair regrowth in all patients without side effects, suggesting potential benefits of this treatment combination, though controlled studies are needed for confirmation.

This review discusses current and emerging therapies for alopecia areata, highlights the challenges in managing this chronic disease, and emphasizes the importance of addressing its psychosocial impacts; it reports no new clinical results.

This article discusses various types of alopecia more common in African-American individuals and reports no clinical results; it highlights the importance of recognizing and differentiating these subtypes for diagnosis and treatment.

This review summarizes existing evidence on the efficacy and safety of JAK inhibitors for treating alopecia areata and emphasizes the need for improved topical formulations.